🇺🇸 FDA
Pipeline program

Vedolizumab

MLN0002/CCT-101

Phase 3 small_molecule completed

Quick answer

Vedolizumab for Ulcerative Colitis is a Phase 3 program (small_molecule) at Takeda with 9 ClinicalTrials.gov record(s).

Program details

Company
Takeda
Indication
Ulcerative Colitis
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials